Cargando…

Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature

Detalles Bibliográficos
Autores principales:	Garrett, Giorgia L., He, Steven Y., Sabouni, Nica, Daud, Adil, Arron, Sarah T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809575/ https://www.ncbi.nlm.nih.gov/pubmed/27051803 http://dx.doi.org/10.1016/j.jdcr.2015.09.020

Ejemplares similares

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2019)

Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients
por: Daud, Adil, et al.
Publicado: (2017)

New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
por: Luke, Jason J, et al.
Publicado: (2014)

A Case of Intracranial Hemorrhage Caused by Combined Dabrafenib and Trametinib Therapy for Metastatic Melanoma
por: Lee, Le Min, et al.
Publicado: (2014)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Retinal Vein Occlusion in a Patient on Dabrafenib and Trametinib Therapy for Metastatic Melanoma
por: Molero-Senosiain, Mercedes, et al.
Publicado: (2022)

Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma
por: Shalata, Walid, et al.
Publicado: (2023)

Primary Melanoma of the Lung Treated with Surgery, Dabrafenib and Trametinib
por: Landgraf, Layla G., et al.
Publicado: (2020)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
por: Balakirouchenane, David, et al.
Publicado: (2020)

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
por: Homet Moreno, Blanca, et al.
Publicado: (2015)

Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report
por: Sundaram, Vinita Ruth, et al.
Publicado: (2018)

Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
por: Draganova, Dafina, et al.
Publicado: (2015)

Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive BRAF Mutant Advanced Melanoma
por: Rossi, Ernesto, et al.
Publicado: (2023)

Ocular toxicity due to Trametinib and Dabrafenib
por: Sarny, Stephanie, et al.
Publicado: (2017)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
por: Atkinson, Victoria G., et al.
Publicado: (2021)

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
por: Minor, David R., et al.
Publicado: (2015)

Dabrafenib/trametinib: Cardiac toxicity: case report
Publicado: (2021)

Dabrafenib plus trametinib for compassionate use in metastatic melanoma: A STROBE-compliant retrospective observational postauthorization study
por: Martín Algarra, Salvador, et al.
Publicado: (2017)

Management of Pyrexia Associated with the Combination of Dabrafenib and Trametinib: Canadian Consensus Statements
por: Thawer, Alia, et al.
Publicado: (2021)

Acute granulomatous interstitial nephritis in a patient with metastatic melanoma on targeted therapy with dabrafenib and trametinib—A case report
por: Krelle, Anna, et al.
Publicado: (2021)

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma
por: Dummer, Reinhard, et al.
Publicado: (2022)

Early Experience with Dabrafenib–Trametinib Combination in Patients with BRAF-Mutated Malignant Melanoma—A Single-Center Experience
por: Ganguly, Sandip, et al.
Publicado: (2021)

Interim analysis for post-marketing surveillance of dabrafenib and trametinib combination therapy in Japanese patients with unresectable and metastatic melanoma with BRAF V600 mutation
por: Teshima, Yasutomo, et al.
Publicado: (2020)

Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
por: Brase, Jan C., et al.
Publicado: (2021)

Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma
por: Frazer, Ricky, et al.
Publicado: (2022)

Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib
por: Kato, Hiroshi, et al.
Publicado: (2023)

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
por: Chapman, Paul B., et al.
Publicado: (2023)

Dabrafenib- and trametinib-associated glomerular toxicity: A case report
por: Jo, Eunmi, et al.
Publicado: (2022)

Ocular side effects of Trametinib and Dabrafenib: a case report
por: Tarım, Bilge, et al.
Publicado: (2023)

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy
por: Mormando, Marilda, et al.
Publicado: (2020)

Monitoring of Dabrafenib and Trametinib in Serum and Self-Sampled Capillary Blood in Patients with BRAFV600-Mutant Melanoma
por: Isberner, Nora, et al.
Publicado: (2022)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G. V., et al.
Publicado: (2017)

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
por: Long, G V, et al.
Publicado: (2019)

Dabrafenib and Trametinib Treatment for Erdheim-Chester Disease With Brain Stem Involvement
por: Al Bayati, Ahmed, et al.
Publicado: (2018)

The Pattern of Progression to First-Line Treatment with Dabrafenib and Trametinib in Patients with Unresectable or Metastatic, BRAF-Mutated, Cutaneous Melanoma: Results of the Observational T-WIN Study
por: Del Vecchio, Michele, et al.
Publicado: (2023)

Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023)

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134
por: Atkins, Michael B., et al.
Publicado: (2023)

Treatment with combined dabrafenib and trametinib in BRAF(V600E)-mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation
por: Brugnara, Sonia, et al.
Publicado: (2018)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k4d0oia74kvbfhrradlavat0kn